Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRATRACHEALGeneric

SURFAXIN

LUCINACTANT

Standard Dose
8.5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SURFAXIN is listed in Drugs@FDA under application 021746 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LUCINACTANT Form and strength SUSPENSION;INTRATRACHEAL - 8.5ML Sponsor LEES PHARM HK Submission history Latest submission status date: 2014-04-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview SURFAXIN is listed in Drugs@FDA under application 021746 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LUCINACTANT Form and strength SUSPENSION;INTRATRACHEAL - 8.5ML Sponsor LEES PHARM HK Submission history Latest submission status date: 2014-04-03 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.